Acute pharmacologic augmentation of psyschotherapy with enhancers of learning or conditioning

• US 20040208923A1
• Filed: 04/22/2004
• Published: 10/21/2004
• Est. Priority Date: 03/29/2001
• Status: Active Grant

• Current Assignee: Kerry J. Ressler, Michael Davis
• Original Assignee: Kerry J. Ressler, Michael Davis
• Inventors: Ressler, Kerry J, Davis, Michael
• Granted Patent: US 7,750,030 B2
• Time in Patent Office: Days
• US Class Current: 424/464
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/215 of carboxylic acids
• CPC Class Codes: A61K 31/42 Oxazoles
• CPC Class Codes: A61K 31/535 having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/30 for treating abuse or dependence
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Methods for treating an individual with a psychiatric order with a pharmacologic agent that enhances learning or conditioning in combination with a session of psychotherapy are provided. These methods of the invention encompass a variety of methods of psychotherapy, and psychodynamically oriented psychotherapy, and psychiatric orders including fear and anxiety disorders, addictive disorders, addictive disorders including substance-abuse disorders, and mood disorders. The pharmacologic agents used for the methods of the present invention are ones that generally enhance learning or conditioning, including those that increase the level of norepinephrine in the brain, those that increase the level of acetylcholine in the brain, and those that enhance N-methyl-D-aspartate (NMDA) receptor transmission in the brain.

Claims

1. A method for treating an individual with a psychiatric disorder, said method comprising an acute administration to the individual of a therapeutically effective amount of a pharmacologic agent that enhances learning or conditioning in combination with a session of psychotherapy.

2. The method of claim 1, wherein said psychotherapy is selected from the group consisting of exposure-based psychotherapy, cognitive psychotherapy, and psychodynamically oriented psychotherapy.

3. The method of claim 2, wherein said psychiatric disorder is selected from the group consisting of a fear and anxiety disorder, an addictive disorder, and a mood disorder.

4. The method of claim 1, wherein said pharmacologic agent is selected from the group consisting of a pharmacologic agent that increases the level of norepinephrine in the brain, a pharmacologic agent that increases the level of acetylcholine in the brain, and a pharmacologic agent that enhances N-methyl-D-aspartate (NMDA) receptor transmission in the brain.

5. The method of claim 4, wherein said pharmacologic agent that increases the level of norepinephrine in the brain is a norepinephrine reuptake inhibitor.

6. The method of claim 5, wherein said norepinephrine reuptake inhibitor is selected from the group consisting of tomoxetine, reboxetine, duloxetine, venlafaxine, and milnacipran.

7. The method of claim 4, wherein said pharmacologic agent that increases the level of norepinephrine in the brain is a pharmacologic agent that causes the release of norepinephrine.

8. The method of claim 7, wherein said pharmacologic agent that causes the release of norepinephrine is selected from the group consisting of amphetamine, dextroamphetamine, pemoline, and methylphenidate.

9. The method of claim 4, wherein said pharmacologic agent that increases the level of acetylcholine in the brain is selected from the group consisting of donepezil HCl and tacrine.

10. The method of claim 4, wherein said pharmacologic agent that enhances NMDA receptor transmission in the brain is a partial NMDA receptor agonist.

11. The method of claim 10, wherein said partial NMDA agonist is selected from the group consisting of D-cycloserine, D-serine, 1-aminocylcopropane-carboxylic acid, spermine, and spermidine.

12. A method for treating an individual with a psychiatric disorder, said method comprising an acute administration to the individual of a therapeutically effective amount of a pharmacologic agent that enhances NMDA receptor transmission in the brain in combination with a session of psychotherapy.

13. The method of claim 12, wherein said acute administration of said therapeutically effective pharmacologic agent occurs within about 12 hours before psychotherapy.

14. The method of claim 13, wherein said psychotherapy is selected from the group consisting of exposure-based psychotherapy, cognitive psychotherapy, and psychodynamically oriented psychotherapy.

15. The method of claim 14, wherein said psychiatric disorder is selected from the group consisting of a fear and anxiety disorder, an addictive disorder, and a mood disorder.

16. The method of claim 13, wherein said pharmacologic agent that enhances NMDA receptor transmission in the brain is a partial NMDA receptor agonist.

17. The method of claim 16, wherein said partial NMDA receptor agonist acts at the glycine modulatory site of the NMDA receptor.

18. The method of claim 17, wherein said partial NMDA receptor agonist is D-cycloserine.

19. The method of claim 18, wherein said D-cycloserine is administered at a dose of between about 30-100 mg.

20. The method of claim 18, wherein said D-cycloserine is administered at a dose of between about 400-500 mg.

21. The method of claim 18, wherein D-alanine is also administered to the individual.

22. The method of claim 17, wherein said partial NMDA receptor agonist is D-serine.

23. The method of claim 17, wherein said partial NMDA receptor agonist is 1-aminocyclopropanecarboxylic acid.

24. The method of claim 16, wherein said partial NMDA receptor agonist is a polyamine.

25. The method of claim 24, where said polyamine is selected from the group consisting of spermine and spermidine.

26. A method for treating an individual with a fear and anxiety disorder, said method comprising an acute administration to the individual of a therapeutically effective amount of a pharmacologic agent that enhances NMDA receptor transmission in the brain in combination with a session of psychotherapy.

27. The method of claim 26, wherein said acute administration of said therapeutically effective pharmacologic agent occurs within about 12 hours before psychotherapy.

28. The method of claim 27, wherein said psychotherapy is selected from the group consisting of exposure-based psychotherapy, cognitive psychotherapy, and psychodynamically oriented psychotherapy.

29. The method of claim 28, wherein said fear and anxiety disorder is selected from the group consisting of panic disorder, specific phobia, post-traumatic stress disorder, obsessive-compulsive disorder, and a movement disorder.

30. The method of claim 29, wherein said pharmacologic agent that enhances NMDA receptor transmission in the brain is a partial NMDA receptor agonist.

31. The method of claim 30, wherein said partial NMDA receptor agonist acts at the glycine modulatory site of the NMDA receptor.

32. The method of claim 31, wherein said partial NMDA receptor agonist is D-cycloserine.

33. The method of claim 32, wherein said D-cycloserine is administered at a dose of between about 30-100 mg.

34. The method of claim 32, wherein said D-cycloserine is administered at a dose of between about 400-500 mg.

35. The method of claim 32, wherein D-alanine is also administered to the individual.

36. The method of claim 31, wherein said partial NMDA receptor agonist is D-serine.

37. The method of claim 31, wherein said partial NMDA receptor agonist is 1-aminocyclopropanecarboxylic acid.

38. The method of claim 30, wherein said partial NMDA receptor agonist is a polyamine.

39. The method of claim 38, where said polyamine is selected from the group consisting of spennine and spermidine.